Comparative_JJ Study_NN of_IN Mechanisms_NNS of_IN Herpes_NP Simplex_NP Virus_NP Inactivation_NP by_IN Sodium_NP Lauryl_NP Sulfate_NP and_CC n-Lauroylsarcosine_JJ The_DT mechanisms_NNS of_IN herpes_NN simplex_JJ virus_NN (_( HSV_NP )_) inactivation_NN by_IN sodium_NN lauryl_NN sulfate_NN (_( SLS_NNS )_) and_CC n-lauroylsarcosine_JJ (_( LS_NP )_) ,_, two_CD anionic_JJ surfactants_NNS with_IN protein_NN denaturant_NN potency_NN ,_, have_VBP been_VBN evaluated_VBN in_IN cultured_JJ cells_NNS ._SENT Results_NNS showed_VBD that_DT pretreatment_NN of_IN HSV_NP type_NN 1_CD (_( HSV-1_NP )_) strain_VBP F_NP and_CC HSV-2_NP strain_VBP 333_CD with_IN either_DT surfactant_NN inhibited_VBD ,_, in_IN a_DT concentration-_NN and_CC time-dependent_JJ manner_NN ,_, their_PP$ infectivities_NNS on_IN Vero_NP cells_NNS ._SENT SLS_NNS was_VBD a_DT more_RBR potent_JJ inhibitor_NN of_IN HSV-2_NP strain_VBP 333_CD infectivity_NN than_IN LS_NP with_IN respect_NN to_TO the_DT concentration_NN (_( 4.8-fold_JJ lower_JJR )_) and_CC time_NN (_( 2.4-fold_JJ shorter_JJR )_) required_VBD to_TO completely_RB inactivate_VB the_DT virus_NN ._SENT No_DT inhibition_NN of_IN both_DT herpesvirus_NN strains_NNS infectivities_NNS was_VBD observed_VBN when_WRB Vero_NP cells_NNS were_VBD pretreated_VBN with_IN either_DT surfactant_NN ._SENT LS_NP prevented_VBD the_DT binding_NN of_IN HSV-2_NP strain_NN 333_CD to_TO cells_NNS without_IN affecting_VBG the_DT stable_JJ attachment_NN and_CC the_DT rate_NN of_IN penetration_NN into_IN cells_NNS ,_, whereas_IN SLS_NNS exerted_VBD the_DT opposite_JJ effect_NN ._SENT Both_DT SLS_NP and_CC LS_NP inhibited_VBD ,_, in_IN a_DT concentration-dependent_JJ manner_NN ,_, the_DT HSV-2_NP strain_NN 333-induced_JJ cytopathic_JJ effect_NN ,_, probably_RB by_IN affecting_VBG newly_RB synthesized_VBN virions_NNS that_WDT come_VBP into_IN contact_NN with_IN surfactant_NN molecules_NNS present_JJ in_IN culture_NN medium_NN ._SENT The_DT pretreatment_NN of_IN HSV-2_NP strain_VBP 333_CD with_IN specific_JJ combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS inhibited_VBD the_DT viral_JJ infectivity_NN in_IN a_DT synergistic_JJ manner_NN and_CC resulted_VBD in_IN only_RB a_DT small_JJ increase_NN in_IN their_PP$ toxicities_NNS for_IN exponentially_RB growing_VBG Vero_NP cells_NNS compared_VBN with_IN that_DT caused_VBN by_IN each_DT compound_NN alone_RB ._SENT Taken_VBN together_RB ,_, these_DT results_NNS suggest_VBP that_IN SLS_NP and_CC LS_NP ,_, alone_RB or_CC combined_VBN ,_, could_MD represent_VB potent_JJ candidates_NNS as_IN microbicides_NNS in_IN topical_JJ vaginal_JJ formulations_NNS to_TO prevent_VB the_DT transmission_NN of_IN herpes_NN and_CC possibly_RB other_JJ pathogens_NNS that_WDT cause_VBP sexually_RB transmitted_JJ diseases_NNS ,_, including_VBG human_JJ immunodeficiency_NN virus_NN type_NN 1_CD ._SENT The_DT number_NN of_IN individuals_NNS infected_VBN with_IN human_JJ immunodeficiency_NN virus_NN type_NN 1_CD (_( HIV-1_NP )_) ,_, herpesviruses_NNS and_CC other_JJ sexually_RB transmitted_VBN pathogens_NNS is_VBZ growing_VBG dramatically_RB worldwide_RB ._SENT The_DT global_JJ incidence_NN ,_, morbidity_NN ,_, and_CC mortality_NN of_IN sexually_RB transmitted_VBN diseases_NNS (_( STDs_NP )_) are_VBP very_RB significant_JJ ._SENT Herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) and_CC HSV-2_NP are_VBP the_DT most_RBS common_JJ causes_NNS of_IN genital_JJ ulceration_NN in_IN developed_JJ countries_NNS ._SENT In_IN the_DT United_NP States_NPS only_RB ,_, approximately_RB 500,000_CD new_JJ cases_NNS of_IN herpes_NN are_VBP reported_VBN each_DT year_NN ._SENT Genital_JJ herpes_NN is_VBZ lifelong_JJ and_CC may_MD result_VB in_IN painful_JJ and_CC recurrent_JJ lesions_NNS ,_, systemic_JJ complications_NNS ,_, and_CC psychosocial_JJ morbidity_NN ._SENT HSVs_NNS are_VBP transmitted_VBN by_IN symptomatic_JJ lesions_NNS and_CC through_IN asymptomatic_JJ viral_JJ shedding_NN ._SENT The_DT high_JJ viral_JJ titers_NNS in_IN symptomatic_JJ lesions_NNS make_VBP this_DT mode_NN of_IN transmission_NN the_DT most_RBS efficient_JJ ._SENT However_RB ,_, the_DT contribution_NN of_IN asymptomatic_JJ viral_JJ shedding_NN to_TO the_DT genital_JJ transmission_NN of_IN herpes_NN in_IN the_DT population_NN may_MD account_VB for_IN as_RB much_JJ as_IN 50_CD to_TO 90_CD %_NN of_IN cases_NNS (_( -_: ,_, )_) ;_: the_DT infected_JJ partner_NN being_VBG unaware_JJ that_IN he_PP or_CC she_PP could_MD transmit_VB the_DT virus_NN ._SENT Moreover_RB ,_, intrapartum_NN transmission_NN of_IN herpes_NN from_IN the_DT mother_NN to_TO the_DT neonate_NN is_VBZ also_RB observed_VBN during_IN vaginal_JJ delivery_NN in_IN 85_CD %_NN of_IN cases_NNS and_CC depends_VBZ on_IN the_DT prevalence_NN of_IN viral_JJ shedding_NN at_IN the_DT time_NN of_IN delivery_NN ._SENT The_DT transmission_NN of_IN the_DT virus_NN to_TO neonates_NNS results_NNS in_IN cutaneous_JJ ,_, mucocutaneous_JJ ,_, or_CC eye_NN infections_NNS or_CC in_IN some_DT cases_NNS in_IN the_DT spreading_VBG of_IN the_DT virus_NN to_TO the_DT brain_NN or_CC internal_JJ organs_NNS ._SENT Latex_NN condoms_NNS represent_VBP an_DT effective_JJ barrier_NN against_IN HIV_NP and_CC other_JJ sexually_RB transmitted_VBN pathogens_NNS ,_, but_CC unfortunately_RB ,_, their_PP$ use_NN is_VBZ not_RB generalized_VBN ._SENT More_JJR attention_NN is_VBZ now_RB given_VBN to_TO female-controlled_JJ methods_NNS to_TO prevent_VB the_DT sexual_JJ transmission_NN of_IN these_DT microorganisms_NNS ,_, since_IN many_JJ women_NNS are_VBP unable_JJ to_TO negotiate_VB condom_NN use_NN with_IN their_PP$ partners_NNS ._SENT Nonoxynol-9_NP ,_, a_DT nonionic_JJ surfactant_NN with_IN membrane-solubilizing_VBG properties_NNS ,_, is_VBZ the_DT most_RBS currently_RB used_VBN active_JJ ingredient_NN in_IN available_JJ vaginal_JJ formulations_NNS ._SENT In_IN vitro_NN ,_, this_DT compound_NN inactivates_VBZ enveloped_VBN viruses_NNS such_JJ as_IN HIV-1_NP and_CC HSV_NP as_RB well_RB as_IN other_JJ microorganisms_NNS ,_, including_VBG Chlamydia_NP trachomatis_NP and_CC Neisseria_NP gonorrhoeae_NNS ,_, but_CC is_VBZ not_RB effective_JJ against_IN nonenveloped_JJ papillomaviruses_NNS ._SENT The_DT activity_NN of_IN nonoxynol-9_NN is_VBZ nonspecific_JJ and_CC is_VBZ often_RB associated_VBN with_IN adverse_JJ effects_NNS ,_, including_VBG epithelial_JJ disruption_NN ,_, genital_JJ inflammation_NN ,_, and_CC ulceration_NN ,_, as_RB well_RB as_IN a_DT reduction_NN in_IN the_DT number_NN of_IN lactobacilli_NNS ,_, which_WDT may_MD explain_VB its_PP$ lack_NN of_IN protection_NN against_IN HIV-1_NP and_CC other_JJ pathogens_NNS causing_VBG STDs_NNS in_IN clinical_JJ trials_NNS (_( ,_, ;_: L._NP Van_NP Damme_NP ,_, plenary_JJ lecture_NN ,_, XIII_NP Int_NP ._SENT AIDS_NP Conf_NP ._SENT ,_, 2000_CD )_) ._SENT There_EX is_VBZ thus_RB an_DT urgent_JJ need_NN to_TO develop_VB new_JJ compounds_NNS which_WDT can_MD be_VB used_VBN as_IN microbicides_NNS in_IN topical_JJ vaginal_JJ formulations_NNS for_IN women_NNS to_TO protect_VB themselves_PP against_IN sexually_RB transmitted_VBN infections_NNS ._SENT Sodium_NN lauryl_NN sulfate_NN (_( SLS_NP )_) ,_, an_DT anionic_JJ surfactant_NN with_IN protein_NN denaturant_NN potency_NN ,_, has_VBZ been_VBN demonstrated_VBN to_TO be_VB a_DT potent_JJ inhibitor_NN of_IN the_DT infectivities_NNS of_IN different_JJ strains_NNS of_IN enveloped_VBN viruses_NNS such_JJ as_IN HSV_NP and_CC HIV-1_NP as_RB well_RB as_IN nonenveloped_JJ viruses_NNS such_JJ as_IN papillomaviruses_NNS in_IN vitro_NN ._SENT We_PP have_VBP also_RB demonstrated_VBN that_DT n-lauroylsarcosine_JJ (_( LS_NP )_) ,_, another_DT anionic_JJ surfactant_NN structurally_RB close_JJ to_TO SLS_NNS ,_, inactivates_VBZ HSV_NP infectivity_NN in_IN vitro_NN ._SENT Moreover_RB ,_, gel_NN formulations_NNS containing_VBG SLS_NP or_CC LS_NP were_VBD very_RB effective_JJ in_IN preventing_VBG HSV-2_JJ infection_NN following_VBG intravaginal_JJ challenge_NN in_IN mice_NNS ._SENT These_DT formulations_NNS were_VBD also_RB well_RB tolerated_VBD following_VBG repeated_JJ intravaginal_JJ administrations_NNS to_TO rabbits_NNS ._SENT These_DT data_NNS suggest_VBP that_IN SLS_NP and_CC LS_NP could_MD represent_VB potent_JJ candidates_NNS for_IN use_NN in_IN topical_JJ vaginal_JJ formulations_NNS to_TO prevent_VB the_DT transmission_NN of_IN HSV_NP ,_, HIV-1_NP ,_, and_CC possibly_RB other_JJ pathogens_NNS causing_VBG STDs_NP ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP have_VBP compared_VBN the_DT mechanisms_NNS of_IN HSV-1_NP and_CC HSV-2_NP inactivation_NN by_IN SLS_NP and_CC LS_NP in_IN cultured_JJ cells_NNS ._SENT We_PP have_VBP also_RB evaluated_VBN the_DT inactivating_VBG potency_NN of_IN combinations_NNS of_IN different_JJ concentrations_NNS of_IN both_DT compounds_NNS on_IN herpesvirus_NN infectivity_NN as_RB well_RB as_IN their_PP$ potential_JJ toxicities_NNS to_TO cells_NNS ._SENT Materials_NNS ._SENT |_SYM SLS_NP and_CC LS_NP were_VBD obtained_VBN from_IN Sigma_NP Chemical_NP Co._NP (_( St._NP Louis_NP ,_, Mo._NP )_) ._SENT [_SYM 3H]methyl_JJ thymidine_NN was_VBD purchased_VBN from_IN Amersham_NP Canada_NP ,_, Ltd._NP (_( Oakville_NP ,_, Ontario_NP ,_, Canada_NP )_) ._SENT Cell_NN lines_NNS ._SENT |_SYM Vero_NP cells_NNS (_( African_JJ green_JJ monkey_NN kidney_NN cells_NNS ;_: American_NP Type_NP Culture_NP Collection_NP ,_, Manassas_NP ,_, Va._NP )_) were_VBD cultivated_VBN in_IN Eagle_NP 's_POS minimum_JJ essential_JJ medium_NN (_( EMEM_NP )_) (_( Canadian_NP Life_NP Technologies_NPS ,_, Burlington_NP ,_, Ontario_NP ,_, Canada_NP )_) supplemented_VBD with_IN sodium_NN bicarbonate_NN (_( 0.22_CD %_NN )_) ,_, penicillin-streptomycin_NN (_( 100_CD U/ml_NP )_) ,_, l-glutamine_NN (_( 2_CD mM_NNS )_) ,_, and_CC 5_CD %_NN heat-inactivated_JJ fetal_JJ bovine_JJ serum_NN (_( FBS_NP )_) (_( Canadian_NP Life_NP Technologies_NP )_) (_( EMEM-5_NP %_NN FBS_NP )_) ._SENT Cultures_NNS were_VBD maintained_VBN at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Virus_NN strains_NNS ._SENT |_SYM HSV-1_NP strain_NN F_NP (_( American_NP Type_NP Culture_NP Collection_NP )_) and_CC HSV-2_NP strain_NN 333_CD (_( kindly_RB provided_VBN by_IN Lawrence_NP R._NP Stanberry_NP ,_, Children_NP 's_POS Hospital_NP Medical_NP Center_NP ,_, Cincinnati_NP ,_, Ohio_NP )_) were_VBD propagated_VBN in_IN Vero_NP cells_NNS in_IN complete_JJ EMEM_NP containing_VBG 2_CD %_NN FBS_NP (_( EMEM-2_NP %_NN FBS_NP )_) ._SENT Preparation_NN of_IN radiolabeled_JJ virus_NN ._SENT |_SYM HSV-2_NP strain_NN 333_CD was_VBD labeled_VBN with_IN [_SYM 3H]methyl_JJ thymidine_NN according_VBG to_TO a_DT previously_RB described_VBN protocol_NN with_IN some_DT modifications_NNS ._SENT In_IN brief_NN ,_, Vero_NP cells_NNS were_VBD incubated_VBN with_IN the_DT virus_NN in_IN EMEM-2_NP %_NN FBS_NP at_IN a_DT multiplicity_NN of_IN infection_NN of_IN 0.1_CD for_IN 1_CD h_NN at_IN 37C_JJ to_TO allow_VB virus_NN adsorption_NN ._SENT The_DT virus_NN was_VBD removed_VBN ,_, and_CC cell_NN sheets_NNS were_VBD washed_VBN twice_RB with_IN culture_NN medium_NN ._SENT Cells_NNS were_VBD then_RB incubated_VBN in_IN EMEM-2_NP %_NN FBS_NP containing_VBG [_SYM 3H]methyl_JJ thymidine_NN (_( 25_CD muCi/ml_NN )_) for_IN 2_CD days_NNS at_IN 37C_JJ ._SENT Cells_NNS and_CC medium_NN were_VBD collected_VBN ,_, frozen_VBN at_IN -80C_NN ,_, and_CC thawed_VBN at_IN 37C_JJ ._SENT The_DT suspension_NN was_VBD centrifuged_VBN (_( 600_CD x_SYM g_NN for_IN 10_CD min_NN at_IN 4C_JJ )_) to_TO pellet_VB cell_NN debris_NN ,_, and_CC the_DT supernatant_JJ (_( 10_CD ml_NN )_) was_VBD layered_VBN over_IN a_DT 3-ml_JJ cushion_NN of_IN 15_CD %_NN sucrose_NN ._SENT Samples_NNS were_VBD centrifuged_VBN (_( 100,000_CD x_SYM g_NN for_IN 2_CD h_NN at_IN 4C_JJ )_) to_TO pellet_VB the_DT virus_NN and_CC resuspended_JJ in_IN 1_CD ml_NN of_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) (_( pH_NN 7.4_CD )_) overnight_RB on_IN ice_NN at_IN 4C_JJ ._SENT The_DT specific_JJ activity_NN of_IN the_DT virus_NN was_VBD approximately_RB 0.33_CD cpm/PFU_NN ._SENT Virus_NN inactivation_NN assay_NN ._SENT |_SYM In_IN a_DT first_JJ set_NN of_IN experiments_NNS ,_, HSV-1_JJ strain_NN F_NN or_CC HSV-2_JJ strain_NN 333_CD was_VBD first_RB preincubated_VBN in_IN PBS_NP (_( control_NN )_) or_CC in_IN PBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN different_JJ periods_NNS of_IN time_NN (_( 0_CD to_TO 60_CD min_NN )_) in_IN a_DT water_NN bath_NN at_IN 37C_JJ ._SENT Confluent_JJ Vero_NP cells_NNS seeded_VBN in_IN 24-well_JJ plates_NNS were_VBD then_RB infected_VBN with_IN pretreated_JJ viruses_NNS (_( approximately_RB 50_CD to_TO 100_CD PFU_NN )_) ._SENT In_IN a_DT second_JJ set_NN of_IN experiments_NNS ,_, the_DT virus_NN and_CC SLS_NP or_CC LS_NP were_VBD added_VBN simultaneously_RB to_TO cells_NNS (_( i.e._FW ,_, in_IN the_DT absence_NN of_IN a_DT pretreatment_NN period_NN )_) ._SENT In_IN a_DT third_JJ set_NN of_IN experiments_NNS ,_, Vero_NP cells_NNS were_VBD preincubated_VBN in_IN PBS_NP (_( control_NN )_) or_CC in_IN PBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD h_NN at_IN 37C_JJ prior_RB to_TO the_DT infection_NN with_IN either_DT HSV-1_NP strain_NN F_NP or_CC HSV-2_NP strain_NN 333_CD ._SENT In_IN all_DT experiments_NNS ,_, the_DT plates_NNS were_VBD immediately_RB centrifuged_VBN (_( 750_CD x_SYM g_NN for_IN 45_CD min_NN at_IN 20C_JJ )_) after_IN the_DT infection_NN of_IN cells_NNS to_TO allow_VB virus_NN adsorption_NN ._SENT Unbound_JJ virus_NN was_VBD removed_VBN by_IN aspiration_NN ,_, and_CC cell_NN sheets_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN (_( Mandel_NP Scientific_NP ,_, St-Laurent_NP ,_, Quebec_NP ,_, Canada_NP )_) ._SENT Cells_NNS were_VBD incubated_VBN for_IN 2_CD days_NNS at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Cells_NNS were_VBD then_RB fixed_VBN with_IN 10_CD %_NN formaldehyde_NN in_IN PBS_NP for_IN 20_CD min_NN ,_, washed_VBN with_IN deionized_JJ water_NN ,_, and_CC stained_VBD with_IN 0.05_CD %_NN methylene_NN blue_NN ._SENT Virus_NN inactivation_NN was_VBD evaluated_VBN from_IN the_DT determination_NN of_IN the_DT numbers_NNS of_IN PFU_NP ._SENT Virus_NN inactivation_NN assay_NN in_IN the_DT presence_NN of_IN proteins_NNS ._SENT |_SYM In_IN a_DT first_JJ set_NN of_IN experiments_NNS ,_, HSV-2_NP strain_NN 333_CD was_VBD preincubated_VBN in_IN EMEM-5_NP %_NN FBS_NP (_( control_NN )_) or_CC in_IN EMEM-5_NP %_NN FBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD h_NN in_IN a_DT water_NN bath_NN at_IN 37C_JJ ._SENT In_IN a_DT second_JJ set_NN of_IN experiments_NNS ,_, the_DT virus_NN was_VBD preincubated_VBN in_IN EMEM_NP containing_VBG increasing_VBG concentrations_NNS of_IN FBS_NP (_( 0_CD to_TO 60_CD %_NN ;_: control_NN )_) or_CC with_IN ,_, in_IN addition_NN ,_, 0.5_CD mM_NP SLS_NNS or_CC 1_CD mM_NP LS_NP for_IN 1_CD h_NN in_IN a_DT water_NN bath_NN at_IN 37C_JJ ._SENT In_IN both_DT cases_NNS ,_, the_DT residual_JJ viral_JJ infectivity_NN was_VBD determined_VBN on_IN Vero_NP cells_NNS as_RB described_VBD above_IN in_IN the_DT virus_NN inactivation_NN assay_NN ._SENT Attachment_NN assay_NN ._SENT |_SYM The_DT effect_NN of_IN SLS_NP and_CC LS_NP on_IN the_DT attachment_NN of_IN radiolabeled_JJ HSV-2_NP strain_NN 333_CD to_TO Vero_NP cells_NNS was_VBD assessed_VBN at_IN 4C_JJ as_IN previously_RB described_VBN ._SENT Confluent_JJ monolayers_NNS of_IN Vero_NP cells_NNS seeded_VBN in_IN 96-well_NN plates_NNS were_VBD first_RB incubated_VBN in_IN PBS_NP plus_CC 1_CD %_NN bovine_JJ serum_NN albumin_NN (_( BSA_NP )_) for_IN 30_CD min_NN at_IN 4C_JJ in_IN order_NN to_TO block_VB nonspecific_JJ virus_NN adsorption_NN ._SENT [_SYM 3H]methyl_JJ thymidine-labeled_JJ HSV-2_NP strain_NN 333_CD was_VBD preincubated_VBN in_IN PBS-1_JJ %_NN BSA_NP (_( control_NN )_) or_CC in_IN PBS-1_JJ %_NN BSA_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD h_NN in_IN a_DT water_NN bath_NN at_IN 37C_JJ ._SENT The_DT viral_JJ suspension_NN was_VBD cooled_VBN in_IN a_DT melting_VBG ice_NN bath_NN for_IN a_DT few_JJ minutes_NNS ._SENT Cells_NNS were_VBD then_RB incubated_VBN with_IN pretreated_JJ virus_NN for_IN 1_CD h_NN at_IN 4C_JJ with_IN gentle_JJ agitation_NN (_( 50_CD to_TO 60_CD rpm_NN )_) ._SENT Cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN ice-cold_JJ PBS_NP and_CC disrupted_VBN with_IN lysis_NN buffer_NN (_( 150_CD mM_NP NaCl_NP ,_, 10_CD mM_NP Tris_NP [_SYM pH_NN 7.6_CD ]_SYM ,_, 1_CD %_NN Igepal_NP CA-630_NP ,_, 1_CD %_NN Na-deoxycholate_NN )_) ._SENT The_DT amount_NN of_IN radioactivity_NN associated_VBN with_IN cell_NN lysates_NNS was_VBD determined_VBN by_IN liquid_JJ scintillation_NN counting_NN ._SENT Postbinding_JJ assay_NN ._SENT |_SYM The_DT effect_NN of_IN SLS_NP and_CC LS_NP on_IN HSV-2_NP strain_VBP 333_CD stably_RB attached_VBN to_TO Vero_NP cells_NNS was_VBD evaluated_VBN as_IN previously_RB described_VBN ._SENT Confluent_JJ Vero_NP cells_NNS seeded_VBN in_IN 24-well_JJ plates_NNS were_VBD maintained_VBN on_IN ice_NN for_IN a_DT few_JJ minutes_NNS ._SENT Cells_NNS were_VBD first_RB incubated_VBN with_IN HSV-2_NP strain_NN 333_CD (_( approximately_RB 50_CD to_TO 100_CD PFU_NN )_) suspended_VBN in_IN PBS_NP for_IN 2_CD h_NN at_IN 4C_JJ to_TO allow_VB a_DT stable_JJ attachment_NN of_IN the_DT virus_NN without_IN fusion_NN with_IN cell_NN membrane_NN ._SENT Unbound_JJ viruses_NNS were_VBD removed_VBN by_IN aspiration_NN ._SENT Cells_NNS were_VBD then_RB washed_VBN with_IN ice-cold_JJ PBS_NP (_( control_NN )_) or_CC with_IN ice-cold_JJ low-pH_NN citrate_NN buffer_NN (_( Na_NP citrate_NN ,_, 40_CD mM_NNS ;_: KCl_NP ,_, 10_CD mM_NNS ;_: NaCl_NP ,_, 135_CD mM_NP ,_, pH_NN 3.0_CD ;_: positive_JJ control_NN )_) or_CC with_IN ice-cold_JJ PBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD min_NN at_IN 4C_JJ ._SENT Cell_NN sheets_NNS were_VBD washed_VBN once_RB with_IN ice-cold_JJ PBS_NP and_CC overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN ._SENT Cells_NNS were_VBD incubated_VBN for_IN 2_CD days_NNS at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Cells_NNS were_VBD then_RB fixed_VBN ,_, washed_VBN ,_, and_CC stained_VBD as_RB described_VBN above_IN ._SENT The_DT amount_NN of_IN virus_NN which_WDT had_VBD penetrated_VBN into_IN cells_NNS after_IN the_DT shift_NN at_IN 37C_NP was_VBD evaluated_VBN following_VBG the_DT determination_NN of_IN the_DT numbers_NNS of_IN PFU_NP ._SENT Penetration_NN assay_NN ._SENT |_SYM The_DT effect_NN of_IN SLS_NP and_CC LS_NP on_IN the_DT rate_NN of_IN penetration_NN of_IN HSV-2_NP strain_VBP 333_CD into_IN Vero_NP cells_NNS was_VBD examined_VBN as_IN previously_RB described_VBN ._SENT In_IN brief_JJ ,_, confluent_JJ monolayers_NNS of_IN Vero_NP cells_NNS seeded_VBN in_IN six-well_NN plates_NNS were_VBD first_RB incubated_VBN with_IN HSV-2_NP strain_VBP 333_CD for_IN 2_CD h_NN at_IN 4C_JJ ._SENT After_IN removal_NN of_IN unbound_JJ viruses_NNS ,_, the_DT plates_NNS were_VBD shifted_VBN to_TO 37C_JJ to_TO allow_VB penetration_NN of_IN virus_NN into_IN cells_NNS ._SENT At_IN selected_JJ times_NNS after_IN the_DT temperature_NN shift_NN (_( 0_CD ,_, 15_CD ,_, 30_CD ,_, and_CC 60_CD min_NN )_) ,_, cells_NNS were_VBD treated_VBN for_IN 1_CD min_NN with_IN PBS_NP (_( control_NN )_) or_CC with_IN PBS_NP containing_VBG 300_CD muM_NN SLS_NNS or_CC 500_CD muM_NN LS_NP prewarmed_VBD at_IN 37C_JJ ._SENT Cells_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN and_CC incubated_VBN for_IN 2_CD days_NNS at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Cells_NNS were_VBD then_RB fixed_VBN ,_, washed_VBN ,_, and_CC stained_VBD as_RB described_VBN above_IN ._SENT The_DT amount_NN of_IN virus_NN which_WDT had_VBD penetrated_VBN into_IN cells_NNS was_VBD evaluated_VBN following_VBG the_DT determination_NN of_IN the_DT numbers_NNS of_IN PFU_NP ._SENT Plaque_NN reduction_NN assay_NN ._SENT |_SYM Confluent_NP Vero_NP cells_NNS seeded_VBN in_IN 24-well_JJ plates_NNS were_VBD first_RB incubated_VBN with_IN HSV-2_NP strain_NN 333_CD (_( approximately_RB 50_CD to_TO 100_CD PFU_NN )_) suspended_VBN in_IN EMEM-2_NP %_NN FBS_NP for_IN 2_CD h_NN at_IN 37C_JJ ._SENT Cells_NNS were_VBD then_RB overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN (_( control_NN )_) or_CC with_IN ,_, in_IN addition_NN ,_, increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP and_CC incubated_VBN for_IN 2_CD days_NNS at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Cells_NNS were_VBD then_RB fixed_VBN ,_, washed_VBN ,_, and_CC stained_VBD as_RB described_VBN above_IN ._SENT Virus-induced_JJ cytopathic_JJ effect_NN was_VBD evaluated_VBN following_VBG the_DT determination_NN of_IN the_DT numbers_NNS of_IN PFU_NP ._SENT Analysis_NN of_IN drug_NN combination_NN effect_NN ._SENT |_SYM The_DT inactivating_VBG potency_NN of_IN different_JJ combinations_NNS of_IN SLS_NP and_CC LS_NP on_IN the_DT infectivity_NN of_IN HSV-2_NP strain_NN 333_CD was_VBD examined_VBN with_IN combinations_NNS of_IN various_JJ concentrations_NNS of_IN the_DT test_NN compounds_NNS in_IN a_DT checkerboard_NN design_NN ._SENT In_IN brief_NN ,_, HSV-2_NP strain_NN 333_CD was_VBD first_RB preincubated_VBN in_IN PBS_NP (_( control_NN )_) or_CC in_IN PBS_NP containing_VBG different_JJ combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS for_IN 1_CD h_NN in_IN a_DT water_NN bath_NN at_IN 37C_JJ ._SENT The_DT residual_JJ viral_JJ infectivity_NN was_VBD then_RB determined_VBN on_IN Vero_NP cells_NNS as_RB described_VBD above_IN in_IN the_DT virus_NN inactivation_NN assay_NN ._SENT The_DT drug_NN combination_NN effect_NN was_VBD analyzed_VBN by_IN the_DT isobologram_NN method_NN as_RB described_VBD previously_RB ._SENT In_IN this_DT analysis_NN ,_, the_DT 50_CD %_NN effective_JJ dose_NN (_( ED50_NP )_) was_VBD used_VBN to_TO calculate_VB the_DT fractional_JJ inhibitory_JJ concentration_NN (_( FIC_NP )_) ._SENT When_WRB the_DT FIC_JJ index_NN of_IN the_DT combined_JJ compounds_NNS (_( i.e._FW ,_, FICx_NP +_SYM FICy_NN )_) is_VBZ equal_JJ to_TO 1.0_CD ,_, the_DT combination_NN is_VBZ assumed_VBN to_TO act_VB in_IN an_DT additive_JJ manner_NN ;_: when_WRB it_PP is_VBZ between_IN 0.5_CD and_CC 1.0_CD ,_, the_DT combination_NN acts_VBZ subsynergistically_RB ;_: and_CC when_WRB it_PP is_VBZ less_JJR than_IN 0.5_CD ,_, it_PP acts_VBZ synergistically_RB ._SENT On_IN the_DT other_JJ hand_NN ,_, when_WRB the_DT FIC_JJ index_NN is_VBZ between_IN 1.0_CD and_CC 2.0_CD ,_, the_DT combination_NN is_VBZ subantagonistic_JJ ,_, and_CC when_WRB it_PP is_VBZ greater_JJR than_IN 2.0_CD ,_, the_DT combination_NN is_VBZ antagonistic_JJ ._SENT Cellular_JJ viability_NN ._SENT |_SYM Vero_NP cells_NNS seeded_VBN at_IN midconfluency_NN in_IN 24-well_JJ plates_NNS were_VBD incubated_VBN in_IN EMEM-5_NP %_NN FBS_NP (_( control_NN )_) or_CC with_IN EMEM-5_NP %_NN FBS_NP containing_VBG different_JJ combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS for_IN 72_CD h_NN at_IN 37C_JJ in_IN a_DT 5_CD %_NN CO2_JJ atmosphere_NN ._SENT Cells_NNS were_VBD washed_VBN once_RB with_IN complete_JJ culture_NN medium_NN and_CC incubated_VBN in_IN EMEM-5_NP %_NN FBS_NP containing_VBG a_DT 100-mug/ml_JJ concentration_NN of_IN a_DT tetrazolium_JJ salt_NN [_SYM 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl]-2H-tetrazolium_JJ ,_, inner_JJ salt_NN [_SYM MTS_NP ]_SYM ;_: Promega_NP ,_, Madison_NP ,_, Wis._NP )_) and_CC phenazine_NN methosulfate_NNS (_( 7.5_CD mug/ml_NN )_) for_IN 30_CD min_NN at_IN 37C_JJ ._SENT The_DT tetrazolium_NN salt_NN is_VBZ reduced_VBN by_IN living_VBG cells_NNS to_TO yield_VB a_DT formazan_JJ product_NN that_WDT can_MD be_VB assayed_VBN colorimetrically_RB ._SENT Reaction_NN mixtures_NNS were_VBD transferred_VBN in_IN a_DT microplate_NN ,_, and_CC the_DT optical_JJ density_NN was_VBD read_VBN at_IN a_DT wavelength_NN of_IN 492_CD nm_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM The_DT significance_NN of_IN the_DT differences_NNS between_IN (_( i_NP )_) the_DT inactivating_VBG potency_NN of_IN SLS_NP and_CC LS_NP on_IN herpesviruses_NNS '_POS infectivities_NNS for_IN susceptible_JJ cells_NNS and_CC (_( ii_NNS )_) the_DT toxic_JJ effect_NN caused_VBN by_IN combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS and_CC each_DT compound_NN alone_RB on_IN the_DT viability_NN of_IN Vero_NP cells_NNS was_VBD evaluated_VBN by_IN an_DT unpaired_JJ Student_NN t_NN test_NN ._SENT All_DT statistical_JJ analyses_NNS were_VBD performed_VBN with_IN a_DT computer_NN package_NN (_( Statview+SE_NP Software_NP ;_: Abacus_NP Concepts_NP ,_, Berkeley_NP ,_, Calif._NP )_) ._SENT A_DT P_NN value_NN of_IN less_JJR than_IN 0.05_CD was_VBD considered_VBN statistically_RB significant_JJ ._SENT Viral_JJ inactivation_NN ._SENT |_SYM Figure_NN shows_VBZ that_DT pretreatment_NN of_IN HSV-1_NP strain_NN F_NP or_CC HSV-2_NP strain_VBP 333_CD with_IN SLS_NNS for_IN 1_CD h_NN at_IN 37C_NP decreased_VBD ,_, in_IN a_DT concentration-dependent_JJ manner_NN ,_, their_PP$ infectivities_NNS for_IN Vero_NP cells_NNS ._SENT The_DT concentrations_NNS of_IN SLS_NNS which_WDT inhibit_VBP 50_CD %_NN (_( ED50_NP )_) and_CC 90_CD %_NN (_( ED90_NP )_) of_IN the_DT infectivity_NN of_IN HSV-1_JJ strain_NN F_NN were_VBD 17.88_CD +-_NN 5.86_CD muM_NN and_CC 34.89_CD +-_NN 10.77_CD muM_NN ,_, respectively_RB ,_, whereas_IN the_DT corresponding_JJ values_NNS for_IN HSV-2_NP strain_NN 333_CD were_VBD 32.67_CD +-_NN 2.18_CD muM_NN and_CC 46.53_CD +-_NN 0.44_CD muM_NN ,_, respectively_RB (_( unless_IN otherwise_RB noted_VBN ,_, results_NNS are_VBP presented_VBN as_IN means_NN +-_NN standard_NN deviations_NNS )_) ._SENT In_IN the_DT absence_NN of_IN a_DT pretreatment_NN period_NN with_IN SLS_NP ,_, the_DT ED50_NP and_CC ED90_NP values_NNS increased_VBD to_TO 70.68_CD +-_NN 5.90_CD muM_NN and_CC 96.04_CD +-_NN 11.20_CD muM_NN for_IN HSV-1_JJ strain_NN F_NN ,_, respectively_RB ,_, and_CC to_TO 54.94_CD +-_NN 6.65_CD muM_NN and_CC 82.29_CD +-_NN 6.75_CD muM_NN for_IN HSV-2_NP strain_NN 333_CD ,_, respectively_RB ._SENT Pretreatment_NN of_IN Vero_NP cells_NNS with_IN SLS_NNS concentrations_NNS up_RB to_TO 300_CD muM_NN for_IN 1_CD h_NN at_IN 37C_JJ prior_RB to_TO viral_JJ infection_NN did_VBD not_RB cause_VB any_DT loss_NN of_IN infectivity_NN for_IN both_DT strains_NNS of_IN herpesviruses_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Similarly_RB ,_, Fig._NN shows_VBZ that_DT pretreatment_NN of_IN both_DT strains_NNS of_IN herpesviruses_NNS with_IN LS_NP reduced_VBD ,_, in_IN a_DT concentration-dependent_JJ manner_NN ,_, their_PP$ infectivities_NNS for_IN Vero_NP cells_NNS ._SENT The_DT ED50_NP and_CC ED90_NP values_NNS obtained_VBD following_VBG pretreatment_NN of_IN HSV-1_JJ strain_NN F_NN with_IN LS_NP for_IN 1_CD h_NN at_IN 37C_NP were_VBD 194.40_CD +-_NN 1.11_CD muM_NN and_CC 329.97_CD +-_NN 16.54_CD muM_NN ,_, respectively_RB ,_, whereas_IN the_DT corresponding_JJ values_NNS for_IN HSV-2_NP strain_NN 333_CD were_VBD 141.76_CD +-_NN 4.10_CD muM_NN and_CC 225.30_CD +-_NN 12.79_CD muM_NN ,_, respectively_RB ._SENT In_IN the_DT absence_NN of_IN a_DT pretreatment_NN period_NN with_IN LS_NP or_CC when_WRB Vero_NP cells_NNS were_VBD pretreated_VBN with_IN LS_NP for_IN 1_CD h_NN at_IN 37C_JJ prior_RB to_TO viral_JJ infection_NN (_( data_NNS not_RB shown_VBN )_) ,_, no_DT significant_JJ inactivation_NN of_IN both_DT herpesvirus_NN strains_VBZ infectivities_NNS could_MD be_VB observed_VBN at_IN concentrations_NNS up_RB to_TO 500_CD muM_NN ._SENT Time_NN course_NN effect_NN ._SENT |_SYM Figure_NN shows_VBZ that_IN the_DT inactivating_VBG potencies_NNS of_IN SLS_NP and_CC LS_NP against_IN HSV-2_NP strain_VBP 333_CD infectivity_NN on_IN Vero_NP cells_NNS were_VBD directly_RB related_VBN to_TO the_DT duration_NN of_IN the_DT viral_JJ pretreatment_NN period_NN ._SENT At_IN equipotent_JJ drug_NN concentrations_NNS ,_, the_DT times_NNS of_IN pretreatment_NN required_VBN to_TO inhibit_VB 50_CD and_CC 90_CD %_NN of_IN viral_JJ infectivity_NN were_VBD 3.27_CD +-_NN 0.86_CD min_NN and_CC 23.10_CD +-_NN 5.28_CD min_NN when_WRB incubated_VBN with_IN 50_CD muM_NN SLS_NNS ,_, respectively_RB ,_, whereas_IN the_DT corresponding_JJ values_NNS after_IN an_DT incubation_NN of_IN the_DT virus_NN with_IN 250_CD muM_NN LS_NP were_VBD 7.32_CD +-_NN 2.86_CD min_NN and_CC 55.41_CD +-_NN 4.50_CD min_NN (_( P_NN <_SYM 0.01_CD compared_VBN with_IN SLS_NP )_) ,_, respectively_RB ._SENT Effect_NN on_IN binding_VBG and_CC postbinding_VBG steps_NNS ._SENT |_SYM Figure_NN shows_VBZ that_DT pretreatment_NN of_IN [_SYM 3H]methyl_JJ thymidine-labeled_JJ HSV-2_NP strain_NN 333_CD with_IN SLS_NNS concentrations_NNS up_RB to_TO 300_CD muM_NN for_IN 1_CD h_NN at_IN 37C_JJ did_VBD not_RB reduce_VB its_PP$ binding_NN to_TO Vero_NP cells_NNS when_WRB assessed_VBN at_IN 4C_JJ ._SENT In_IN contrast_NN ,_, pretreatment_NN of_IN the_DT radiolabeled_JJ virus_NN with_IN LS_NP for_IN 1_CD h_NN at_IN 37C_NP decreased_VBD ,_, in_IN a_DT concentration-dependent_JJ manner_NN ,_, the_DT initial_JJ attachment_NN of_IN the_DT virus_NN to_TO cell_NN surface_NN heparan_NN sulfate_NN ._SENT The_DT 50_CD %_NN reduction_NN of_IN viral_JJ binding_NN was_VBD observed_VBN at_IN an_DT LS_NP concentration_NN of_IN 139.08_CD +-_NN 34.10_CD muM_NN ,_, which_WDT corresponds_VBZ with_IN the_DT ED50_NP obtained_VBD for_IN the_DT inhibition_NN of_IN viral_JJ infectivity_NN (_( i.e._FW ,_, 141.76_CD +-_NN 4.10_CD muM_NN )_) ._SENT We_PP also_RB obtained_VBD a_DT correlation_NN coefficient_NN between_IN infectivity_NN and_CC binding_JJ data_NNS of_IN 0.918_CD ,_, which_WDT suggests_VBZ that_DT elimination_NN of_IN the_DT viral_JJ attachment_NN step_NN is_VBZ probably_RB the_DT principal_JJ mode_NN of_IN inhibition_NN of_IN herpesvirus_NN infectivities_NNS by_IN LS_NP ._SENT Figure_NN shows_VBZ that_IN SLS_NP ,_, added_VBD to_TO cell_NN cultures_NNS after_IN the_DT initial_JJ viral_JJ binding_JJ period_NN at_IN 4C_JJ ,_, was_VBD able_JJ to_TO inhibit_VB the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD stably_RB attached_VBN to_TO Vero_NP cells_NNS ._SENT The_DT ED50_NP and_CC ED90_NP values_NNS were_VBD 204.71_CD +-_NN 25.98_CD muM_NN and_CC 297.16_CD +-_NN 24.66_CD muM_NN ,_, respectively_RB ._SENT However_RB ,_, the_DT concentrations_NNS of_IN SLS_NNS required_VBN to_TO inhibit_VB the_DT virus_NN infectivity_NN under_IN these_DT conditions_NNS were_VBD 3.5-fold_JJ higher_JJR than_IN that_DT needed_VBN to_TO inhibit_VB its_PP$ infectivity_NN in_IN the_DT absence_NN of_IN a_DT viral_JJ pretreatment_NN period_NN ._SENT In_IN contrast_NN ,_, LS_NP concentrations_NNS up_RB to_TO 300_CD muM_NN had_VBD no_DT effect_NN on_IN viruses_NNS stably_RB attached_VBN to_TO cells_NNS ._SENT Treatment_NN of_IN HSV-2_NP strain_VBP 333_CD stably_RB attached_VBN to_TO cells_NNS with_IN a_DT low-pH_NN citrate_NN buffer_NN (_( positive_JJ control_NN )_) for_IN 1_CD min_NN at_IN 4C_NP reduced_VBD to_TO 1.87_CD %_NN +-_NN 0.82_CD %_NN of_IN control_NN values_VBZ the_DT amount_NN of_IN virus_NN which_WDT had_VBD penetrated_VBN into_IN cells_NNS after_IN the_DT shift_NN at_IN 37C_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT Effect_NN on_IN rate_NN of_IN penetration_NN into_IN cells_NNS ._SENT |_SYM Figure_NN shows_VBZ that_IN SLS_NNS ,_, at_IN a_DT concentration_NN of_IN 300_CD muM_NN ,_, decreases_VBZ the_DT rate_NN of_IN penetration_NN of_IN HSV-2_NP strain_VBP 333_CD in_IN Vero_NP cells_NNS ._SENT The_DT inhibitory_JJ effect_NN was_VBD more_RBR pronounced_VBN when_WRB the_DT 1-min_JJ treatment_NN period_NN with_IN SLS_NNS was_VBD made_VBN 15_CD or_CC 30_CD min_NN (_( approximately_RB 90_CD %_NN inhibition_NN )_) compared_VBN to_TO 60_CD min_NN (_( approximately_RB 40_CD %_NN decrease_NN )_) after_IN the_DT temperature_NN shift_NN at_IN 37C_JJ ._SENT In_IN contrast_NN ,_, LS_NP ,_, at_IN a_DT concentration_NN of_IN 500_CD muM_NN ,_, had_VBD no_DT effect_NN on_IN the_DT rate_NN of_IN penetration_NN of_IN the_DT virus_NN into_IN cells_NNS at_IN any_DT time_NN after_IN the_DT temperature_NN shift_NN at_IN 37C_JJ ._SENT Effect_NN on_IN virus-induced_JJ cytopathic_JJ effect_NN ._SENT |_SYM Figure_NN shows_VBZ that_IN SLS_NP and_CC LS_NP ,_, added_VBD to_TO Vero_NP cells_NNS infected_VBN with_IN HSV-2_NP strain_VBP 333_CD after_IN a_DT 2-h_JJ incubation_NN period_NN at_IN 37C_JJ ,_, reduced_VBN in_IN a_DT concentration-dependent_JJ manner_NN the_DT virus-induced_JJ cytopathic_JJ effect_NN ._SENT The_DT concentrations_NNS of_IN SLS_NNS required_VBN to_TO reduce_VB the_DT virus-induced_JJ cytopathic_JJ effect_NN by_IN 50_CD and_CC 90_CD %_NN were_VBD 77.61_CD +-_NN 4.86_CD muM_NN and_CC 109.28_CD +-_NN 20.42_CD muM_NN ,_, respectively_RB ,_, whereas_IN the_DT corresponding_JJ values_NNS for_IN LS_NP were_VBD 81.36_CD +-_NN 11.26_CD muM_NN and_CC 114.81_CD +-_NN 9.88_CD muM_NN ,_, respectively_RB ._SENT Inhibitory_JJ effect_NN of_IN combinations_NNS of_IN surfactants_NNS ._SENT |_SYM Table_NP shows_VBZ the_DT inhibitory_JJ effects_NNS of_IN various_JJ combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS on_IN the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD for_IN Vero_NP cells_NNS following_VBG a_DT 1-h_NP viral_JJ pretreatment_NN period_NN at_IN 37C_JJ ._SENT The_DT inhibitory_JJ effects_NNS of_IN combinations_NNS of_IN both_DT compounds_NNS on_IN viral_JJ infectivity_NN were_VBD analyzed_VBN by_IN the_DT isobologram_NN method_NN ._SENT Different_JJ effects_NNS were_VBD observed_VBN depending_VBG on_IN the_DT concentrations_NNS of_IN surfactants_NNS mixed_VBN together_RB ._SENT Combinations_NNS of_IN SLS_NP and_CC LS_NP acted_VBD synergistically_RB to_TO inactivate_VB the_DT virus_NN infectivity_NN when_WRB LS_NP concentrations_NNS between_IN 12.5_CD and_CC 50_CD muM_NN were_VBD added_VBN to_TO increasing_VBG SLS_NNS concentrations_NNS ._SENT Combinations_NNS of_IN LS_NP and_CC SLS_NP acted_VBD synergistically_RB when_WRB 12.5_CD muM_NN SLS_NNS was_VBD added_VBN to_TO increasing_VBG LS_NP concentrations_NNS ,_, whereas_IN subsynergistic_JJ effects_NNS were_VBD obtained_VBN in_IN the_DT presence_NN of_IN 20_CD or_CC 25_CD muM_NN SLS_NNS ._SENT Cellular_JJ viability_NN ._SENT |_SYM Table_NP shows_VBZ the_DT effects_NNS of_IN different_JJ concentrations_NNS of_IN SLS_NP or_CC LS_NP ,_, alone_JJ or_CC combined_JJ ,_, on_IN the_DT viability_NN of_IN exponentially_RB growing_VBG Vero_NP cells_NNS following_VBG a_DT 72-h_NP incubation_NN period_NN ._SENT SLS_NP and_CC LS_NP alone_RB decreased_VBD ,_, in_IN a_DT concentration-dependent_JJ manner_NN ,_, the_DT viabilities_NNS of_IN these_DT cells_NNS ._SENT The_DT 50_CD %_NN cytotoxic_JJ concentrations_NNS (_( CC50_NP )_) of_IN SLS_NP and_CC LS_NP to_TO this_DT cell_NN line_NN were_VBD 202.04_CD +-_NN 13.07_CD muM_NN and_CC 265.61_CD +-_NN 10.74_CD muM_NN ,_, respectively_RB ._SENT The_DT CC50_NP of_IN SLS_NP and_CC LS_NP on_IN resting_JJ Vero_NP cell_NN cultures_NNS incubated_VBN with_IN either_DT surfactant_NN for_IN 24_CD h_NN were_VBD 266.30_CD +-_NN 29.09_CD muM_NN and_CC 345.84_CD +-_NN 11.79_CD muM_NN ,_, respectively_RB (_( data_NNS not_RB shown_VBN )_) ._SENT Combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS similar_JJ to_TO those_DT tested_VBN for_IN their_PP$ inhibitory_JJ effects_NNS on_IN viral_JJ infectivity_NN induced_VBD a_DT significant_JJ decrease_NN of_IN the_DT viability_NN of_IN exponentially_RB growing_VBG cells_NNS compared_VBN with_IN each_DT compound_NN alone_RB ._SENT Inhibitory_JJ effect_NN of_IN SLS_NP and_CC LS_NP in_IN the_DT presence_NN of_IN proteins_NNS ._SENT |_SYM Figure_NN shows_VBZ that_IN the_DT concentrations_NNS of_IN SLS_NP and_CC LS_NP required_VBD to_TO inhibit_VB the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD on_IN Vero_NP cells_NNS in_IN complete_JJ culture_NN medium_NN (_( EMEM-5_NP %_NN FBS_NP )_) were_VBD about_RB 5.1_CD and_CC 2.5_CD times_NNS higher_RBR ,_, respectively_RB ,_, compared_VBN with_IN viral_JJ pretreatment_NN in_IN PBS_NP ._SENT The_DT ED50_NP and_CC ED90_NP values_NNS obtained_VBD following_VBG a_DT viral_JJ pretreatment_NN period_NN of_IN 1_CD h_NN at_IN 37C_JJ with_IN SLS_NNS in_IN EMEM-5_NP %_NN FBS_NP were_VBD 185.41_CD +-_NN 3.52_CD muM_NN and_CC 207.63_CD +-_NN 6.01_CD muM_NN ,_, respectively_RB ,_, whereas_IN the_DT corresponding_JJ values_NNS for_IN LS_NP were_VBD 384.86_CD +-_NN 20.71_CD muM_NN and_CC 490.64_CD +-_NN 23.08_CD muM_NN ._SENT Figure_NN shows_VBZ the_DT effect_NN of_IN increasing_VBG FBS_NP concentrations_NNS on_IN the_DT inhibitory_JJ potencies_NNS of_IN SLS_NP and_CC LS_NP on_IN the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD on_IN Vero_NP cells_NNS ._SENT Pretreatment_NN of_IN HSV-2_NP strain_VBP 333_CD with_IN 500_CD muM_NN SLS_NNS for_IN 1_CD h_NN at_IN 37C_JJ inhibited_VBN viral_JJ infectivity_NN at_IN FBS_NP concentrations_NNS of_IN 10_CD %_NN and_CC lower_JJR ._SENT About_RB 90_CD %_NN of_IN the_DT viral_JJ infectivity_NN was_VBD inhibited_VBN when_WRB the_DT virus_NN was_VBD pretreated_VBN with_IN 1_CD mM_NP LS_NP in_IN culture_NN medium_NN containing_VBG 20_CD %_NN FBS_NP ._SENT At_IN higher_JJR FBS_NP concentrations_NNS ,_, the_DT viral_JJ infectivity_NN was_VBD not_RB affected_VBN by_IN either_DT surfactant_NN treatment_NN ,_, probably_RB because_IN SLS_NP and_CC LS_NP were_VBD bound_VBN to_TO serum_NN proteins_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Effect_NN of_IN SLS_NP (_( A_NP and_CC B_NP )_) and_CC LS_NP (_( C_NP and_CC D_NP )_) on_IN the_DT infectivities_NNS of_IN HSV-1_JJ strain_NN F_NN and_CC HSV-2_JJ strain_NN 333_CD (_( *_SYM )_) on_IN Vero_NP cells_NNS ._SENT Effect_NN of_IN SLS_NP (_( A_NP and_CC B_NP )_) and_CC LS_NP (_( C_NP and_CC D_NP )_) on_IN the_DT infectivities_NNS of_IN HSV-1_JJ strain_NN F_NN and_CC HSV-2_JJ strain_NN 333_CD (_( *_SYM )_) on_IN Vero_NP cells_NNS ._SENT In_IN a_DT first_JJ set_NN of_IN experiments_NNS ,_, confluent_JJ cell_NN monolayers_NNS were_VBD inoculated_VBN with_IN viruses_NNS pretreated_VBN with_IN PBS_NP (_( control_NN )_) or_CC with_IN PBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN surfactants_NNS for_IN 1_CD h_NN at_IN 37C_JJ (_( A_NP and_CC C_NP )_) ._SENT In_IN a_DT second_JJ set_NN of_IN experiments_NNS ,_, surfactants_NNS and_CC viruses_NNS were_VBD added_VBN simultaneously_RB to_TO cells_NNS without_IN any_DT pretreatment_NN period_NN (_( B_NP and_CC D_NP )_) ._SENT In_IN both_DT cases_NNS ,_, the_DT plates_NNS were_VBD immediately_RB centrifuged_VBN (_( 750_CD x_SYM g_NN for_IN 45_CD min_NN at_IN 20C_JJ )_) to_TO allow_VB virus_NN adsorption_NN ._SENT Unbound_JJ viruses_NNS were_VBD removed_VBN by_IN aspiration_NN ._SENT Cell_NN sheets_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN and_CC incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Infectivity_NN was_VBD expressed_VBN as_IN the_DT percentage_NN of_IN PFU_NP compared_VBN with_IN that_IN of_IN control_NN cells_NNS ._SENT Results_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 2_CD ._SENT |_SYM Time_NP course_NN effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD on_IN Vero_NP cells_NNS ._SENT Time_NN course_NN effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD on_IN Vero_NP cells_NNS ._SENT Confluent_JJ cells_NNS were_VBD inoculated_VBN with_IN viruses_NNS pretreated_VBN with_IN PBS_NP (_( control_NN )_) or_CC with_IN PBS_NP containing_VBG 50_CD muM_NN SLS_NNS or_CC 250_CD muM_NN LS_NP for_IN various_JJ periods_NNS of_IN time_NN (_( 0_CD to_TO 60_CD min_NN )_) ._SENT The_DT plates_NNS were_VBD then_RB immediately_RB centrifuged_VBD (_( 750_CD x_SYM g_NN for_IN 45_CD min_NN at_IN 20C_JJ )_) to_TO allow_VB virus_NN adsorption_NN ._SENT Unbound_JJ viruses_NNS were_VBD removed_VBN by_IN aspiration_NN ._SENT Cell_NN sheets_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN and_CC incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Infectivity_NN was_VBD expressed_VBN as_IN the_DT percentage_NN of_IN PFU_NP compared_VBN with_IN that_DT observed_VBN for_IN control_NN cells_NNS ._SENT Results_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM (_( A_NP )_) Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN the_DT attachment_NN of_IN [_SYM 3H]methyl_JJ thymidine-labeled_JJ HSV-2_NP strain_NN 333_CD to_TO Vero_NP cells_NNS ._SENT (_( A_NP )_) Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN the_DT attachment_NN of_IN [_SYM 3H]methyl_JJ thymidine-labeled_JJ HSV-2_NP strain_NN 333_CD to_TO Vero_NP cells_NNS ._SENT Viruses_NNS were_VBD first_RB pretreated_VBN with_IN PBS_NP plus_CC 1_CD %_NN BSA_NP (_( control_NN )_) or_CC with_IN PBS-1_JJ %_NN BSA_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD h_NN at_IN 37C_JJ ._SENT Confluent_JJ cells_NNS were_VBD then_RB incubated_VBN with_IN pretreated_JJ viruses_NNS for_IN 1_CD h_NN at_IN 4C_JJ ._SENT Cells_NNS were_VBD washed_VBN three_CD times_NNS with_IN PBS_NP and_CC lysed_VBN ,_, and_CC radioactivity_NN associated_VBN with_IN cell_NN lysates_NNS was_VBD determined_VBN by_IN liquid_JJ scintillation_NN counting_NN ._SENT Binding_VBG was_VBD expressed_VBN as_IN the_DT percentage_NN of_IN counts_NNS per_IN minute_NN in_IN the_DT control_NN cell_NN lysates_NNS ._SENT Results_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT (_( B_NP )_) Correlation_NP calculated_VBN between_IN inhibition_NN of_IN viral_JJ infectivity_NN and_CC inhibition_NN of_IN viral_JJ attachment_NN data_NNS obtained_VBD following_VBG pretreatment_NN of_IN HSV-2_NP strain_VBP 333_CD with_IN increasing_VBG LS_NP concentrations_NNS for_IN 1_CD h_NN at_IN 37C_JJ ._SENT FIG._NN 4_CD ._SENT |_SYM Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333_CD stably_RB attached_VBN to_TO Vero_NP cells_NNS ._SENT Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333_CD stably_RB attached_VBN to_TO Vero_NP cells_NNS ._SENT Virus_NN was_VBD first_RB adsorbed_VBN to_TO the_DT confluent_JJ cell_NN monolayer_NN by_IN a_DT 2-h_JJ incubation_NN period_NN at_IN 4C_JJ ._SENT After_IN removal_NN of_IN unbound_JJ viruses_NNS ,_, cells_NNS were_VBD treated_VBN with_IN ice-cold_JJ PBS_NP (_( control_NN )_) or_CC with_IN ice-cold_JJ PBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD min_NN at_IN 4C_JJ ._SENT Cells_NNS were_VBD washed_VBN once_RB with_IN ice-cold_JJ PBS_NP ,_, overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN ,_, and_CC incubated_VBD for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Results_NNS were_VBD expressed_VBN as_IN the_DT percentage_NN of_IN PFU_NP compared_VBN with_IN that_IN of_IN control_NN cells_NNS ._SENT Values_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 5_CD ._SENT |_SYM Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN the_DT rate_NN of_IN penetration_NN of_IN HSV-2_NP strain_VBP 333_CD in_IN Vero_NP cells_NNS ._SENT Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN the_DT rate_NN of_IN penetration_NN of_IN HSV-2_NP strain_VBP 333_CD in_IN Vero_NP cells_NNS ._SENT Virus_NN was_VBD first_RB adsorbed_VBN to_TO the_DT confluent_JJ cell_NN monolayer_NN after_IN a_DT 2-h_JJ incubation_NN period_NN at_IN 4C_JJ ._SENT After_IN removal_NN of_IN unbound_JJ viruses_NNS ,_, cells_NNS were_VBD shifted_VBN to_TO 37C_JJ to_TO allow_VB penetration_NN into_IN cells_NNS ._SENT At_IN selected_JJ times_NNS after_IN the_DT temperature_NN shift_NN (_( 0_CD ,_, 15_CD ,_, 30_CD ,_, and_CC 60_CD min_NN )_) ,_, cells_NNS were_VBD treated_VBN for_IN 1_CD min_NN with_IN PBS_NP (_( control_NN )_) or_CC PBS_NP containing_VBG 300_CD muM_NN SLS_NNS or_CC 500_CD muM_NN LS_NP prewarmed_VBD at_IN 37C_JJ ._SENT Cell_NN sheets_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN and_CC incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Results_NNS were_VBD expressed_VBN as_IN the_DT number_NN of_IN PFU_NP ._SENT Values_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 6_CD ._SENT |_SYM Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333-induced_JJ cytopathic_JJ effect_NN on_IN Vero_NP cells_NNS ._SENT Effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333-induced_JJ cytopathic_JJ effect_NN on_IN Vero_NP cells_NNS ._SENT Virus_NN was_VBD first_RB adsorbed_VBN to_TO confluent_JJ cell_NN monolayers_NNS by_IN a_DT 2-h_JJ incubation_NN period_NN at_IN 37C_JJ ._SENT Unbound_JJ viruses_NNS were_VBD removed_VBN by_IN aspiration_NN ._SENT Cell_NN sheets_NNS were_VBD then_RB overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN (_( control_NN )_) or_CC with_IN ,_, in_IN addition_NN ,_, increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP and_CC incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Results_NNS are_VBP expressed_VBN as_IN the_DT percentage_NN of_IN PFU_NP compared_VBN with_IN that_IN of_IN control_NN cells_NNS ._SENT Values_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 7_CD ._SENT |_SYM Inhibitory_JJ effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333_CD infectivity_NN in_IN complete_JJ culture_NN medium_NN (_( EMEM-5_NP %_NN FBS_NP )_) ._SENT Inhibitory_JJ effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333_CD infectivity_NN in_IN complete_JJ culture_NN medium_NN (_( EMEM-5_NP %_NN FBS_NP )_) ._SENT Confluent_JJ Vero_NP cells_NNS were_VBD inoculated_VBN with_IN viruses_NNS pretreated_VBN with_IN EMEM-5_NP %_NN FBS_NP (_( control_NN )_) or_CC with_IN EMEM-5_NP %_NN FBS_NP containing_VBG increasing_VBG concentrations_NNS of_IN SLS_NP or_CC LS_NP for_IN 1_CD h_NN at_IN 37C_JJ ._SENT The_DT plates_NNS were_VBD then_RB immediately_RB centrifuged_VBD (_( 750_CD x_SYM g_NN for_IN 45_CD min_NN at_IN 20C_JJ )_) to_TO allow_VB virus_NN adsorption_NN ._SENT Unbound_JJ viruses_NNS were_VBD removed_VBN by_IN aspiration_NN ._SENT Cell_NN sheets_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN and_CC incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Infectivity_NN was_VBD expressed_VBN as_IN the_DT percentage_NN of_IN PFU_NP compared_VBN with_IN that_IN of_IN control_NN cells_NNS ._SENT Results_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT FIG._NN 8_CD ._SENT |_SYM Inhibitory_JJ effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333_CD infectivity_NN in_IN the_DT presence_NN of_IN increasing_VBG amounts_NNS of_IN fetal_JJ bovine_JJ serum_NN ._SENT Inhibitory_JJ effect_NN of_IN SLS_NP and_CC LS_NP (_( *_SYM )_) on_IN HSV-2_NP strain_VBP 333_CD infectivity_NN in_IN the_DT presence_NN of_IN increasing_VBG amounts_NNS of_IN fetal_JJ bovine_JJ serum_NN ._SENT Confluent_JJ cells_NNS were_VBD inoculated_VBN with_IN viruses_NNS pretreated_VBN with_IN EMEM_NP containing_VBG increasing_VBG amounts_NNS of_IN FBS_NP (_( 0_CD to_TO 60_CD %_NN ;_: control_NN )_) or_CC with_IN ,_, in_IN addition_NN ,_, 500_CD muM_NN SLS_NNS or_CC 1_CD mM_NP LS_NP for_IN 1_CD h_NN at_IN 37C_JJ ._SENT The_DT plates_NNS were_VBD immediately_RB centrifuged_VBN (_( 750_CD x_SYM g_NN for_IN 45_CD min_NN at_IN 20C_JJ )_) to_TO allow_VB virus_NN adsorption_NN ._SENT Unbound_JJ viruses_NNS were_VBD removed_VBN by_IN aspiration_NN ._SENT Cell_NN sheets_NNS were_VBD overlaid_VBN with_IN EMEM-2_NP %_NN FBS_NP containing_VBG 0.6_CD %_NN SeaPlaque_NN agarose_NN and_CC incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ ._SENT Infectivity_NN was_VBD expressed_VBN as_IN the_DT percentage_NN of_IN PFU_NP compared_VBN with_IN that_IN of_IN control_NN cells_NNS ._SENT Results_NNS are_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( error_NN bars_NNS )_) of_IN three_CD independent_JJ experiments_NNS ._SENT TABLE_NN 1_CD |_SYM Inhibitory_JJ effects_NNS of_IN different_JJ combinations_NNS of_IN SLS_NP and_CC LS_NP concentrations_NNS on_IN the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD on_IN Vero_NP cells_NNS after_IN a_DT 1-h_NP pretreatment_NN period_NN at_IN 37C_JJ TABLE_NP 2_CD |_SYM Effects_VBZ of_IN SLS_NP and_CC LS_NP ,_, alone_JJ or_CC combined_JJ ,_, on_IN the_DT viability_NN of_IN exponentionally_RB growing_VBG Vero_NP cells_NNS after_IN a_DT 72-h_NP incubation_NN period_NN The_DT development_NN of_IN safe_JJ and_CC effective_JJ topical_JJ vaginal_JJ microbicides_NNS is_VBZ a_DT high_JJ priority_NN for_IN major_JJ health_NN organizations_NNS ._SENT SLS_NP and_CC LS_NP ,_, two_CD anionic_JJ surfactants_NNS with_IN protein_NN denaturant_NN potency_NN ,_, are_VBP potential_JJ candidates_NNS for_IN use_NN as_IN microbicides_NNS in_IN topical_JJ vaginal_JJ formulations_NNS (_( reviewed_VBN in_IN reference_NN )_) ._SENT In_IN the_DT present_JJ study_NN ,_, we_PP have_VBP examined_VBN the_DT mechanism(s)_NN by_IN which_WDT SLS_NP and_CC LS_NP inactivate_VBP HSV_NP infectivities_NNS in_IN cultured_JJ cells_NNS ._SENT We_PP have_VBP also_RB evaluated_VBN the_DT efficacies_NNS of_IN several_JJ combinations_NNS of_IN both_DT surfactant_NN concentrations_NNS to_TO inhibit_VB viral_JJ infectivity_NN in_IN relation_NN to_TO their_PP$ effects_NNS on_IN cell_NN viability_NN ._SENT As_IN we_PP have_VBP previously_RB shown_VBN ,_, SLS_NP is_VBZ a_DT potent_JJ inhibitor_NN of_IN HSV-1_JJ strain_NN F_NN and_CC HSV-2_JJ strain_NN 333_CD infectivities_NNS for_IN Vero_NP cells_NNS ._SENT Howett_NP et_FW al._FW have_VBP also_RB reported_VBN that_DT pretreatment_NN of_IN HSV-2_NP strain_VBP 333_CD with_IN SLS_NNS at_IN a_DT concentration_NN of_IN 867_CD muM_NN for_IN 10_CD min_NN at_IN 37C_NP completely_RB inactivated_VBD the_DT infectivity_NN of_IN the_DT virus_NN for_IN CV-1_JJ cells_NNS ._SENT The_DT difference_NN between_IN the_DT doses_NNS of_IN SLS_NNS required_VBN to_TO completely_RB inactivate_VB the_DT virus_NN obtained_VBN by_IN the_DT two_CD groups_NNS probably_RB relates_VBZ to_TO the_DT cell_NN lines_NNS used_VBN (_( CV-1_NP versus_CC Vero_NP cells_NNS )_) ._SENT Moreover_RB ,_, the_DT use_NN of_IN complete_JJ culture_NN medium_NN containing_VBG 10_CD %_NN serum_NN ,_, compared_VBN to_TO PBS_NP in_IN our_PP$ studies_NNS ,_, may_MD decrease_VB the_DT surfactant_NN availability_NN due_JJ to_TO the_DT high_JJ affinity_NN of_IN SLS_NNS for_IN the_DT proteins_NNS present_JJ in_IN the_DT culture_NN medium_NN ._SENT In_IN that_DT respect_NN ,_, we_PP showed_VBD that_IN ,_, under_IN our_PP$ experimental_JJ conditions_NNS ,_, the_DT use_NN of_IN complete_JJ culture_NN medium_NN (_( EMEM-5_NP %_NN FBS_NP )_) ,_, rather_RB than_IN PBS_NP ,_, resulted_VBN in_IN a_DT fivefold-increased_JJ concentration_NN of_IN SLS_NNS required_VBN to_TO inhibit_VB viral_JJ infectivity_NN ._SENT LS_NP ,_, which_WDT is_VBZ structurally_RB close_JJ to_TO SLS_NNS ,_, is_VBZ also_RB a_DT potent_JJ inactivator_NN of_IN HSV-1_JJ strain_NN F_NN and_CC HSV-2_JJ strain_NN 333_CD infectivities_NNS for_IN Vero_NP cells_NNS ._SENT The_DT inhibitory_JJ potencies_NNS of_IN SLS_NP and_CC LS_NP against_IN both_DT strains_NNS of_IN herpesviruses_NNS were_VBD directly_RB related_VBN to_TO the_DT duration_NN of_IN the_DT viral_JJ pretreatment_NN period_NN ._SENT In_IN addition_NN ,_, no_DT inactivation_NN was_VBD observed_VBN when_WRB Vero_NP cells_NNS were_VBD pretreated_VBN with_IN either_DT surfactant_NN rather_RB than_IN the_DT virus_NN ,_, suggesting_VBG that_IN these_DT compounds_NNS act_VBP mainly_RB on_IN viral_JJ particles_NNS ._SENT Compared_VBN with_IN SLS_NP ,_, the_DT concentration_NN of_IN LS_NP required_VBD to_TO completely_RB inactivate_VB the_DT infectivity_NN of_IN HSV-2_NP strain_VBP 333_CD following_VBG a_DT 1-h_NP viral_JJ pretreatment_NN period_NN at_IN 37C_NP was_VBD fivefold_RB higher_JJR ._SENT In_IN addition_NN ,_, at_IN equipotent_JJ compound_NN concentrations_NNS ,_, LS_NP completely_RB inactivat_NN 